Illustration: Aïda Amer/Axios
Successful biopharma IPO debuts are rebounding this spring amid pent-up demand for biotechs with good science.
Yes, but: Repeated upsized offerings pricing at the top of their ranges suggest companies and their bankers remain cautious about investor demand.
